Abstract 3219
Background
Individuals newly diagnosed with cancer may experience impairments in several aspects of health and often have a high need for both information and support. Approximately 30 % will experience symptoms of anxiety and depression with varying needs of support. E-health interventions such as internet-based interactive health communication applications (IHCAs) may offer a supplement to standard care services. Developers of such interventions need to work closely with presumptive users to add relevance and value. The purpose was to explore the user experiences of an IHCA targeting individuals with breast- colorectal or prostate cancer with symptoms of anxiety and depression.
Methods
A qualitative study with inductive approach was conducted, where 15 individuals using an IHCA targeting symptoms of anxiety and depression were interviewed with semi-structured questions. Content analysis was used to analyze interviews.
Results
The need for information was described as high, and almost looked upon as a survival strategy when newly diagnosed. The IHCA was experienced as a useful, reliable source of information and support, and was used as a complement to standard care. Increased knowledge was a foundation for continued processing of own feelings and the favorable time to get access to the IHCA was when being informed of the diagnose. The common denominator was that of being acknowledged but with a further desire for individual adjustment to own situation and needs.
Conclusions
The IHCA was experienced as a safe and reliable complement to standard care. Similar interventions may gain from a more individualized content, being integrated in to standard care and/or by using tracking of symptoms to adjust the content. Offering the IHCA closer to diagnosis may provide more benefits to users.
Clinical trial identification
NCT-01630681.
Editorial acknowledgement
Legal entity responsible for the study
Regional Committee for Research Ethics Sweden, Uppsala county (Dnr 2012/003/9).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract